BioTime (BTX)
BioTime Revenue Growth: -23.37%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BTX Revenue Growth Rankings
| Overall | 6th percentile | 4083 of 4358 |
| Sector | 12th percentile | 401 of 456 in Healthcare |
| Industry | 20th percentile | 100 of 126 in Biotechnology |
BTX Revenue Growth Range, Past 5 Years
| Minimum | -25.33% | Dec 2007 |
| Maximum | 162.6% | Dec 2009 |
| Average | 40.12% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these BTX related companies
BTX News
BioTime and Subsidiary LifeMap Sciences Announce Agreement to Market MalaCards
May 22, 8:45AM Benzinga
May 22, 8:45AM Benzinga
CORRECTION: BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments
May 10, 9:55PM Thomson Reuters ONE
May 10, 9:55PM Thomson Reuters ONE
BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments
May 10, 5:05PM Thomson Reuters ONE
May 10, 5:05PM Thomson Reuters ONE
BioTime’s Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development
Apr 23, 3:30PM Business Wire
Apr 23, 3:30PM Business Wire
BioTime’s Subsidiary OncoCyte Corporation Provides Update on PanC-DxTM, and Related Diagnostic Products
Apr 23, 2:23PM Business Wire
Apr 23, 2:23PM Business Wire
BioTime's Subsidiary Cell Cure Neurosciences Provides Update on OpRegen® Product Development
Apr 23, 2:14PM Benzinga
Apr 23, 2:14PM Benzinga
BioTime’s Subsidiary Cell Cure Neurosciences, Ltd. Provides Update on OpRegen® Product Development
Apr 23, 2:13PM Business Wire
Apr 23, 2:13PM Business Wire
Listen to $BTX BioTime at BioCentury & Thomson Reuters Future Leaders in the Bio - live at 09:00 AM, ondemand after - http://stks.co/3Qsu
about 38 days ago by earningscast
about 38 days ago by earningscast
BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX
Apr 20, 8:46AM Benzinga
Apr 20, 8:46AM Benzinga
BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX, Inc.
Apr 20, 8:45AM Business Wire
Apr 20, 8:45AM Business Wire
$BTX Morning star and follow through. 11% short. RSI 34. Double bottom.
about 40 days ago by Lookatthesky
about 40 days ago by Lookatthesky
$BTX CEO Michael D. West to Present at the Future Leaders in Biotech Industry Conference (Apr 20 at 9 am) http://stks.co/3OZv
about 40 days ago by abubnic
about 40 days ago by abubnic
BioTime CEO Michael D. West to Present at the Future Leaders in the Biotech Industry Conference
Apr 18, 8:45AM Business Wire
Apr 18, 8:45AM Business Wire
BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012
Apr 16, 8:45AM Business Wire
Apr 16, 8:45AM Business Wire
BioTime CEO Michael D. West to Present at 2012 Maxim Group Growth Conference
Mar 21, 4:14PM Business Wire
Mar 21, 4:14PM Business Wire
$BTX http://stks.co/2BWt Nice J-Hook Pattern with strong upmove and small retracement. Buy the breakout.
about 117 days ago by Master1981
about 117 days ago by Master1981
keep $edap on your watch list...$btx is nice too (obama stem cell play)
about 124 days ago by MarketMaker
about 124 days ago by MarketMaker
$BTX http://stks.co/1ihW its a sloptart.a bit all over the place but very powerful.looking to nibble 5.5 then add on break
about 150 days ago by kunal00
about 150 days ago by kunal00
RT @djaparidze1 Pump and DUMP..... $BTX http://stks.co/1fgg // working out well
about 157 days ago by djaparidze1
about 157 days ago by djaparidze1
@traderstewie agreed, Shorted $BTX at 6 yesterday. what ya think about $SWHC?
about 157 days ago by djaparidze1
about 157 days ago by djaparidze1
$BTX 200 Day SMA Cross - Price crossed above 200 day SMA (5.2508). Confirmed by volume.
about 160 days ago by TradeIdeasQuant
about 160 days ago by TradeIdeasQuant
$BTX completes HyStem-Rx preclinical ISO 10993 studies - safety/biocompatibility of stem cell delivery products. http://stks.co/1Uln
about 168 days ago by abubnic
about 168 days ago by abubnic
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BTX | 4.21 | -0.05 | -1.17% | 211.85M |
| BTUI | 2.90 | +0.00 | +0.00% | 27.55M |
| BTU | 23.88 | +0.02 | +0.08% | 6.502B |
| BTN | 6.40 | -0.02 | -0.31% | 91.33M |
| BTM | 12.01 | +0.19 | +1.61% | 1.600B |
| CDTI | 2.63 | +0.22 | +9.13% | 18.99M |
| CDR | 4.61 | -0.07 | -1.50% | 319.57M |
| CDNS | 10.29 | -0.12 | -1.15% | 2.824B |
| CDII | 0.3401 | +0.02 | +5.29% | 13.87M |
| CDI | 16.70 | -0.22 | -1.30% | 320.31M |
